RELA and colorectal carcinoma: Combined with the results of network pharmacology, molecular docking, and experimental verification of cell and animal and human tissue samples at three levels, PM promotes colorectal cell apoptosis and inhibits the development of CRC mainly by inhibiting the expression of RelA. Among the five bioactive ingredients associated with CRC in PM, kaempferol and RelA had the highest molecular docking level.